Ipsen will be launching a new pre-filled syringe for its blockbuster rare disease drug Somatuline (lanreotide) in the EU. The new design was based on several studies, involving patients ...

Ipsen has also made no secret it is in a drive to replenish its pipeline as it faces erosion of its top-selling drug Somatuline (lanreotide), a therapy for acromegaly and neuroendocrine tumours ...